Linked-in: Design and efficacy of antibody drug conjugates in oncology

Oncotarget

Volumn 4, Issue 3, 2013, Pages 397-412

  Feld, Jonathan ^a   Barta, Stefan K ^a   Schinke, Carolina ^a   Braunschweig, Ira ^a   Zhou, Yiyu ^a   Verma, Amit K ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Antibody drug conjugates; Immunotoxins; Oncotargets

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; BL 22; BLEOMYCIN; BRENTUXIMAB VEDOTIN; BRYOSTATIN 1; CAPECITABINE; CAT 3888; CD19 ANTIGEN; CD22 ANTIGEN; CD30 ANTIGEN; COMBOTOX; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; IMMUNOTOXIN; INOTUZUMAB OZOGAMICIN; KADCYCLA; LAPATINIB; MOXETUMOMAB PASUDOTOX; PACLITAXEL; PREDNISONE; RITUXIMAB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ACUTE LYMPHOBLASTIC LEUKEMIA; ANEMIA; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRALGIA; ARTICLE; ASTHENIA; B CELL LEUKEMIA; B CELL LYMPHOMA; BINDING AFFINITY; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST METASTASIS; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CELLULITIS; CHRONIC LYMPHATIC LEUKEMIA; CIRCULATING TUMOR CELL; CONSTIPATION; COUGHING; CYTOKINE RELEASE SYNDROME; CYTOPENIA; DECREASED APPETITE; DIARRHEA; DISEASE FREE SURVIVAL; DIZZINESS; DOSE RESPONSE; DRUG APPROVAL; DRUG BINDING; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; EPISTAXIS; EYE DISEASE; FATIGUE; FEBRILE NEUTROPENIA; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; HAIRY CELL LEUKEMIA; HEAD AND NECK EDEMA; HEMOLYTIC UREMIC SYNDROME; HODGKIN DISEASE; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERPLASIA; HYPERTRANSAMINASEMIA; HYPOALBUMINEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOXIA; IMMUNOGENICITY; INFECTION; LARGE CELL LYMPHOMA; LEUKOPENIA; LIMB PAIN; LIVER FUNCTION TEST; LIVER TOXICITY; LUNG CONGESTION; LYMPHOCYTOPENIA; MANTLE CELL LYMPHOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MOUTH ULCER; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; NK T CELL LYMPHOMA; NODULAR REGENERATIVE HYPERPLASIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PANCREATITIS; PERIPHERAL EDEMA; PERIPHERAL MOTOR NEUROPATHY; PERIPHERAL NEUROPATHY; PERIPHERAL SENSORY NEUROPATHY; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROSTATITIS; PROTEINURIA; PRURITUS; PULMONARY HYPERTENSION; SEPSIS; SEVERE COMBINED IMMUNODEFICIENCY; SIDE EFFECT; STEM CELL TRANSPLANTATION; SYNDROME; T CELL LYMPHOMA; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR FLARE; UNSPECIFIED SIDE EFFECT; VASCULAR LEAK SYNDROME; VOMITING; WEIGHT GAIN; XEROSTOMIA;

EID: 84879007299     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.924     Document Type: Article

References (98)

1. Strebhardt K and Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008; 8(6):473-480.
2. Mathe G, LO TB and Bernard J. Effect on mouse leukemia 1210 of a combination by diazo-reaction of amethopterin and gamma-globulins from hamsters inoculated with leukemia by heterografts. C R Hebd Seances Acad Sci. 1958; 246(10):1626-1628.
3. Piascik PP. FDA approves fusion protein for treatment of lymphoma. J Am Pharm Assoc (Wash). 1999; 39(4):571-572.
4. Leget GA and Czuczman MS. Use of rituximab, the new FDA-approved antibody. Current Opinion in Oncology. 1998; 10(6):548-551.
5. Hussain N. Ligand-mediated tissue specific drug delivery. Advanced Drug Delivery Reviews. 2000; 43(2-3):95-100.
6. Goodman LS, Wintrobe MM, Damehek W, Goodman MJ, Gilman A, McLennan MT. Nitrogen mustard therapy: Use of methyl-bis(beta-chloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. JAMA. 1984; 251(17):2255-2261.
7. Polson AG, Calemine-Fenaux J, Chan P, Chang W, Christensen E, Clark S, de Sauvage FJ, Eaton D, Elkins K, Elliott JM, Frantz G, Fuji RN, Gray A, Harden K, Ingle GS, Kljavin NM, et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res. 2009; 69(6):2358-2364.
8. Erickson HK, Widdison WC, Mayo MF, Whiteman K, Audette C, Wilhelm SD and Singh R. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem. 2010; 21(1):84-92.
9. Alley SC, Benjamin DR, Jeffrey SC, Okeley NM, Meyer DL, Sanderson RJ and Senter PD. Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates. Bioconjugate Chemistry. 2008; 19(3):759-765.
10. Crocker PR, McMillan SJ and Richards HE. CD33-related siglecs as potential modulators of inflammatory responses. Annals of the New York Academy of Sciences. 2012; 1253(1):102-111.
11. Tedder TF and Isaacs CM. Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamily. The Journal of Immunology. 1989; 143(2):712-717.
12. Wilson GL, Fox CH, Fauci AS and Kehrl JH. cDNA cloning of the B cell membrane protein CD22: a mediator of B-B cell interactions. The Journal of Experimental Medicine. 1991; 173(1):137-146.
13. Hynes NE and Stern DF. The biology of erbB-2/nue/HER-2 and its role in cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1994; 1198(2-3):165-184.
14. Soler-Rodriguez AM, Uhr JW, Richardson J and Vitetta ES. The toxicity of chemically deglycosylated ricin A-chain in mice. International Journal of Immunopharmacology. 1992; 14(2):281-291.
15. Kato J, O'Donnell RT, Abuhay M and Tuscano JM. Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's lymphoma. OncoImmunology. 2012; 1(9):1469-1475.
16. Morris JC and Waldmann TA. Antibody-based therapy of leukaemia. Expert Reviews in Molecular Medicine. 2009; 11:null-null.
17. Du X, Beers R, FitzGerald DJ and Pastan I. Differential Cellular Internalization of Anti-CD19 and -CD22 Immunotoxins Results in Different Cytotoxic Activity. Cancer Research. 2008; 68(15):6300-6305.
18. Ghetie M, Tucker K, Richardson J, Uhr J and Vitetta E. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin. Blood. 1992; 80(9):2315-2320.
19. Messmann RA, Vitetta ES, Headlee D, Senderowicz AM, Figg WD, Schindler J, Michiel DF, Creekmore S, Steinberg SM, Kohler D, Jaffe ES, Stetler-Stevenson M, Chen H, Ghetie V and Sausville EA. A Phase I Study of Combination Therapy with Immunotoxins IgG-HD37-Deglycosylated Ricin A Chain (dgA) and IgG-RFB4-dgA (Combotox) in Patients with Refractory CD19(+), CD22(+) B Cell Lymphoma. Clinical Cancer Research. 2000; 6(4):1302-1313.
20. Herrera L, Farah RA, Pellegrini VA, Aquino DB, Sandler ES, Buchanan GR and Vitetta ES. Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. Leukemia. 2000; 14(5):853-858.
21. Herrera L, Yarbrough S, Ghetie V, Aquino DB and Vitetta ES. Treatment of SCID//human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins. Leukemia. 2003; 17(2):334-338.
22. Herrera LMD, Bostrom BMD, Gore LMD, Sandler EMD, Lew GMD, Schlegel PGMD, Aquino VMD, Ghetie VP, Vitetta ESP and Schindler JP. A Phase 1 Study of Combotox in Pediatric Patients With Refractory B-lineage Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology. 2009; 31(12):936-941.
23. Schindler J, Gajavelli S, Ravandi F, Shen Y, Parekh S, Braunchweig I, Barta S, Ghetie V, Vitetta E and Verma A. A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia. British Journal of Haematology. 2011; 154(4):471-476.
24. Barta SK, Zou Y, Schindler J, Shenoy N, Bhagat TD, Steidl U and Verma A. Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia. Leukemia & Lymphoma. 2012; 53(10):1999-2003.
25. Younes A, Yasothan U and Kirkpatrick P. Brentuximab vedotin. Nat Rev Drug Discov. 2012; 11(1):19-20.
26. Deutsch YE, Tadmor T, Podack ER and Rosenblatt JD. CD30: an important new target in hematologic malignancies. Leukemia & Lymphoma. 2011; 52(9):1641-1654.
27. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, Law C-L, Doronina SO, Siegall CB, Senter PD and Wahl AF. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003; 102(4):1458-1465.
28. Hamblett KJ, Senter PD, Chace DF, Sun MMC, Lenox J, Cerveny CG, Kissler KM, Bernhardt SX, Kopcha AK, Zabinski RF, Meyer DL and Francisco JA. Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate. Clinical Cancer Research. 2004; 10(20):7063-7070.
29. Sanderson RJ, Hering MA, James SF, Sun MMC, Doronina SO, Siadak AW, Senter PD and Wahl AF. In vivo Drug-Linker Stability of an Anti-CD30 Dipeptide-Linked Auristatin Immunoconjugate. Clinical Cancer Research. 2005; 11(2):843-852.
30. Sutherland MSK, Sanderson RJ, Gordon KA, Andreyka J, Cerveny CG, Yu C, Lewis TS, Meyer DL, Zabinski RF, Doronina SO, Senter PD, Law C-L and Wahl AF. Lysosomal Trafficking and Cysteine Protease Metabolism Confer Target-specific Cytotoxicity by Peptide-linked Anti-CD30-Auristatin Conjugates. Journal of Biological Chemistry. 2006; 281(15):10540-10547.
31. Oflazoglu E, Kissler KM, Sievers EL, Grewal IS and Gerber H-P. Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. British Journal of Haematology. 2008; 142(1):69-73.
32. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL and Forero-Torres A. Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas. New England Journal of Medicine. 2010; 363(19):1812-1821.
33. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, et al. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma. Journal of Clinical Oncology. 2012; 30(18):2183-2189.
34. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA and Shustov A. Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study. Journal of Clinical Oncology. 2012; 30(18):2190-2196.
35. Fanale MA, Forero-Torres A, Rosenblatt JD, Advani RH, Franklin AR, Kennedy DA, Han TH, Sievers EL and Bartlett NL. A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies. Clinical Cancer Research. 2012; 18(1):248-255.
36. Wagner-Johnston ND, Bartlett NL, Cashen A and Berger JR. Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. Leukemia & Lymphoma. 2012; 53(11):2283-2286.
37. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blattler WA, Lambert JM, Chari RVJ, Lutz RJ, Wong WLT, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, et al. Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate. Cancer Research. 2008; 68(22):9280-9290.
38. Erickson HK, Lewis Phillips GD, Leipold DD, Provenzano CA, Mai E, Johnson HA, Gunter B, Audette CA, Gupta M, Pinkas J and Tibbitts J. The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates. Molecular Cancer Therapeutics. 2012; 11(5):1133-1142.
39. Chen X, Nguyen M, Jacobson F and Ouyang J. Charge-based analysis of antibodies with engineered cysteines: From multiple peaks to a single main peak. mAbs. 2009; 1(6):563-571.
40. Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS, Lu Y, Meng YG, Ng C, Yang J, Lee CC, Duenas E, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotech. 2008; 26(8):925-932.
41. Junutula JR, Flagella KM, Graham RA, Parsons KL, Ha E, Raab H, Bhakta S, Nguyen T, Dugger DL, Li G, Mai E, Lewis Phillips GD, Hiraragi H, Fuji RN, Tibbitts J, Vandlen R, et al. Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Clinical Cancer Research. 2010; 16(19):4769-4778.
42. Junttila TT, Li G, Parsons K, Phillips GL and Sliwkowski MX. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Research and Treatment. 2011; 128(2):347-356.
43. Barok M, Tanner M, Koninki K and Isola J. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Research. 2011; 13(2):R46.
44. Cufí S, Corominas-Faja B, Vazquez-Martin A, Oliveras-Ferraros C, Dorca J, Bosch-Barrera J, Martin-Castillo B and Menendez JA. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. Oncotarget. 2012; 3(4):395-398.
45. Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, Girish S, Tibbitts J, Yi J-H, Sliwkowski MX, Jacobson F, Lutzker SG and Burris HA. Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer. Journal of Clinical Oncology. 2010; 28(16):2698-2704.
46. Burris HA, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, Amler L, Zheng M, Chu Y-W, Klencke B and O'Shaughnessy JA. Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer After Prior HER2-Directed Therapy. Journal of Clinical Oncology. 2011; 29(4):398-405.
47. Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, Guardino E, Lu M, Zheng M, Girish S, Amler L, Winer EP and Rugo HS. A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine. Journal of Clinical Oncology. 2012; 30(26):3234-3241.
48. Beeram M, Krop IE, Burris HA, Girish SR, Yu W, Lu MW, Holden SN and Modi S. A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. Cancer. 2012:118(23):5733-5740.
49. Olson EM, Lin NU, DiPiro PJ, Najita JS, Krop IE, Winer EP and Burstein HJ. Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. Annals of Oncology. 2012; 23(1):93-97.
50. Thon JN, Devine MT, Jurak Begonja A, Tibbitts J and Italiano JE. High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)-mediated inhibition of platelet production. Blood. 2012; 120(10):1975-1984.
51. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh D-Y, Dieras Vr, Guardino E, Fang L, Lu MW, Olsen S and Blackwell K. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. New England Journal of Medicine. 2012; 367(19):1783-1791.
52. Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, Guardino E, Song C, Tong B, Ng V, Chu Y-W and Perez EA. Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. Journal of Clinical Oncology. 2013.
53. Mansfield E, Pastan I and FitzGerald DJ. Characterization of RFB4-Pseudomonas Exotoxin A Immunotoxins Targeted to CD22 on B-Cell Malignancies. Bioconjugate Chemistry. 1996; 7(5):557-563.
54. Mansfield E, Amlot P, Pastan I and FitzGerald DJ. Recombinant RFB4 Immunotoxins Exhibit Potent Cytotoxic Activity for CD22-Bearing Cells and Tumors. Blood. 1997; 90(5):2020-2026.
55. Kreitman RJ, Wang Q-C, FitzGerald DJP and Pastan I. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys. International Journal of Cancer. 1999; 81(1):148-155.
56. Kreitman RJ, Margulies I, Stetler-Stevenson M, Wang Q-C, FitzGerald DJP and Pastan I. Cytotoxic Activity of Disulfide-stabilized Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) toward Fresh Malignant Cells from Patients with B-Cell Leukemias. Clinical Cancer Research. 2000; 6(4):1476-1487.
57. Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ and Pastan I. Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia. New England Journal of Medicine. 2001; 345(4):241-247.
58. Salvatore G, Beers R, Margulies I, Kreitman RJ and Pastan I. Improved Cytotoxic Activity toward Cell Lines and Fresh Leukemia Cells of a Mutant Anti-CD22 Immunotoxin Obtained by Antibody Phage Display. Clinical Cancer Research. 2002; 8(4):995-1002.
59. Bang S, Nagata S, Onda M, Kreitman RJ and Pastan I. HA22 (R490A) Is a Recombinant Immunotoxin with Increased Antitumor Activity without an Increase in Animal Toxicity. Clinical Cancer Research. 2005; 11(4):1545-1550.
60. Ho M, Kreitman RJ, Onda M and Pastan I. In Vitro Antibody Evolution Targeting Germline Hot Spots to Increase Activity of an Anti-CD22 Immunotoxin. Journal of Biological Chemistry. 2005; 280(1):607-617.
61. Onda M, Beers R, Xiang L, Nagata S, Wang Q-c and Pastan I. An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proceedings of the National Academy of Sciences. 2008; 105(32):11311-11316.
62. Weldon JE, Xiang L, Chertov O, Margulies I, Kreitman RJ, FitzGerald DJ and Pastan I. A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood. 2009; 113(16):3792-3800.
63. Onda M, Beers R, Xiang L, Lee B, Weldon JE, Kreitman RJ and Pastan I. Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proceedings of the National Academy of Sciences. 2011; 108(14):5742-5747.
64. Liu W, Onda M, Lee B, Kreitman RJ, Hassan R, Xiang L and Pastan I. Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proceedings of the National Academy of Sciences. 2012; 109(29):11782-11787.
65. Keppler-Hafkemeyer A, Kreitman RJ and Pastan I. Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies. International Journal of Cancer. 2000; 87(1):86-94.
66. Decker T, Oelsner M, Kreitman RJ, Salvatore G, Wang Q-c, Pastan I, Peschel C and Licht T. Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins. Blood. 2004; 103(7):2718-2726.
67. Bogner C, Dechow T, Ringshausen I, Wagner M, Oelsner M, Lutzny G, Licht T, Peschel C, Pastan I, Kreitman RJ and Decker T. Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression. British Journal of Haematology. 2010; 148(1):99-109.
68. Kreitman RJ, Squires DR, Stetler-Stevenson M, Noel P, FitzGerald DJP, Wilson WH and Pastan I. Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies. Journal of Clinical Oncology. 2005; 23(27):6719-6729.
69. Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, FitzGerald DJP, Wilson WH and Pastan I. Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia. Journal of Clinical Oncology. 2009; 27(18):2983-2990.
70. Wayne AS, Kreitman RJ, Findley HW, Lew G, Delbrook C, Steinberg SM, Stetler-Stevenson M, FitzGerald DJ and Pastan I. Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial. Clinical Cancer Research. 2010; 16(6):1894-1903.
71. Biberacher V, Decker T, Oelsner M, Wagner M, Bogner C, Schmidt B, Kreitman RJ, Peschel C, Pastan I, Meyer zum Buschenfelde C and Ringshausen I. The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion. Haematologica. 2012; 97(5):771-779.
72. Li Z, Mahesh SP, Shen DF, Liu B, Siu WO, Hwang FS, Wang Q-C, Chan C-C, Pastan I and Nussenblatt RB. Eradication of Tumor Colonization and Invasion by a B Cell-Specific Immunotoxin in a Murine Model for Human Primary Intraocular Lymphoma. Cancer Research. 2006; 66(21):10586-10593.
73. Alderson RF, Kreitman RJ, Chen T, Yeung P, Herbst R, Fox JA and Pastan I. CAT-8015: A Second-Generation Pseudomonas Exotoxin A-Based Immunotherapy Targeting CD22-Expressing Hematologic Malignancies. Clinical Cancer Research. 2009; 15(3):832-839.
74. Mussai F, Campana D, Bhojwani D, Stetler-Stevenson M, Steinberg SM, Wayne AS and Pastan I. Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia. British Journal of Haematology. 2010; 150(3):352-358.
75. Wei H, Xiang L, Wayne AS, Chertov O, FitzGerald DJ, Bera TK and Pastan I. Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy. Proceedings of the National Academy of Sciences. 2012; 109(18):6898-6903.
76. Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, FitzGerald DJ, Lechleider R and Pastan I. Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia. Journal of Clinical Oncology. 2012; 30(15):1822-1828.
77. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G and Pazdur R. Approval Summary. Clinical Cancer Research. 2001; 7(6):1490-1496.
78. Estey E. Treatment of AML: resurrection for gemtuzumab ozogamicin? Lancet. 2012; 379(9825):1468-1469.
79. Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie JN, Legrand O, Thomas X, Turlure P, Reman O, de Revel T, Gastaud L, de Gunzburg N, Contentin N, Henry E, Marolleau JP, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012; 379(9825):1508-1516.
80. Burnett AK, Russell NH, Hills RK, Kell J, Freeman S, Kjeldsen L, Hunter AE, Yin J, Craddock CF, Dufva IH, Wheatley K and Milligan D. Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia. Journal of Clinical Oncology. 2012; 30(32):3924-3931.
81. DiJoseph JF, Popplewell A, Tickle S, Ladyman H, Lawson A, Kunz A, Khandke K, Armellino DC, Boghaert ER, Hamann PR, Zinkewich-Peotti K, Stephens S, Weir N and Damle NK. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22. Cancer Immunology, Immunotherapy. 2005; 54(1):11-24.
82. DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L, Kunz A, Hamann PR, Gorovits B, Udata C, Moran JK, Popplewell AG, Stephens S, Frost P and Damle NK. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood. 2004; 103(5):1807-1814.
83. DiJoseph JF, Goad ME, Dougher MM, Boghaert ER, Kunz A, Hamann PR and Damle NK. Potent and Specific Antitumor Efficacy of CMC-544, a CD22-Targeted Immunoconjugate of Calicheamicin, against Systemically Disseminated B-Cell Lymphoma. Clinical Cancer Research. 2004; 10(24):8620-8629.
84. DiJoseph JF, Dougher MM, Kalyandrug LB, Armellino DC, Boghaert ER, Hamann PR, Moran JK and Damle NK. Antitumor Efficacy of a Combination of CMC-544 (Inotuzumab Ozogamicin), a CD22-Targeted Cytotoxic Immunoconjugate of Calicheamicin, and Rituximab against Non-Hodgkin's B-Cell Lymphoma. Clinical Cancer Research. 2006; 12(1):242-249.
85. DiJoseph JF, Dougher MM, Armellino DC, Evans DY and Damle NK. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia. 2007; 21(11):2240-2245.
86. DiJoseph J, Dougher M, Evans D, Zhou B-B and Damle N. Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP. Cancer Chemotherapy and Pharmacology. 2011; 67(4):741-749.
87. Takeshita A, Shinjo K, Yamakage N, Ono T, Hirano I, Matsui H, Shigeno K, Nakamura S, Tobita T, Maekawa M, Ohnishi K, Sugimoto Y, Kiyoi H, Naoe T and Ohno R. CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma. British Journal of Haematology. 2009; 146(1):34-43.
88. Takeshita A, Yamakage N, Shinjo K, Ono T, Hirano I, Nakamura S, Shigeno K, Tobita T, Maekawa M, Kiyoi H, Naoe T, Ohnishi K, Sugimoto Y and Ohno R. CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells. Leukemia. 2009; 23(7):1329-1336.
89. de Vries JF, Zwaan CM, De Bie M, Voerman JSA, den Boer ML, van Dongen JJM and van der Velden VHJ. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia. 2012; 26(2):255-264.
90. Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E, Gisselbrecht C, Ketterer N, Nasta S, Rohatiner A, Schmidt-Wolf IGH, Schuler M, Sierra J, Smith MR, Verhoef G, Winter JN, et al. Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study. Journal of Clinical Oncology. 2010; 28(12):2085-2093.
91. Ogura M, Tobinai K, Hatake K, Uchida T, Kasai M, Oyama T, Suzuki T, Kobayashi Y, Watanabe T, Azuma T, Mori M, Terui Y, Yokoyama M, Mishima Y, Takahashi S, Ono C, et al. Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. Cancer Science. 2010; 101(8):1840-1845.
92. Ogura M, Hatake K, Ando K, Tobinai K, Tokushige K, Ono C, Ishibashi T and Vandendries E. Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma. Cancer Science. 2012; 103(5):933-938.
93. Fayad L, Offner F, Smith MR, Verhoef G, Johnson P, Kaufman JL, Rohatiner A, Advani A, Foran J, Hess G, Coiffier B, Czuczman M, Gine E, Durrant S, Kneissl M, Luu KT, et al. Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab. Journal of Clinical Oncology. 2013.
94. Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, York S, Ravandi F, Kwari M, Faderl S, Rios MB, Cortes J, Fayad L, Tarnai R, Wang SA, Champlin R, et al. Inotuzumab ozogamicin, an anti-CD22?calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. The Lancet Oncology. 2012; 13(4):403-411.
95. von Deimling A, Sahm F and Capper D. Mutation specific antibodies: tool or dinosaur? Oncotarget. 2012; 3(9):907-908.
96. Aurisicchio L, Marra E, Roscilli G, Mancini R and Ciliberto G. The promise of anti-ErbB3 monoclonals as new cancer therapeutics. Oncotarget. 2012; 3(8):744-758.
97. Guo K, Tang JP, Li J, Tan CP, Al-Aidaroos AQO, Hong CW, Varghese L, Feng ZW, Park JE, Zhou JB, Chng WJ and Zeng Q. Engineering the First Chimeric Antibody in Targeting Intracellular PRL-3 Oncoprotein for Cancer Therapy in Mice. Oncotarget 2012; 3(2):158-171.
98. Schlaak M, Schmidt P, Bangard C, Kurschat P, Mauch C and Abken H. Regression of metastatic melanoma in a patient by antibody targeting of cancer stem cells. Oncotarget. 2012; 3(1):22-30.